版本:
中国

BRIEF-European Medicines Agency's CHMP recommends approval of Merck's keytruda

March 24 Merck & Co Inc:

* European Medicines Agency's CHMP recommends approval of Merck's keytruda (pembrolizumab) for the treatment of patients with relapsed or refractory classical hodgkin lymphoma

* Merck & Co Inc- decision on approval is expected in Q2 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐